Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Su... | NCT04341116 | Trialant
NCT04341116
Sponsor
I-Mab Biopharma US Limited
Status
Completed
Last Update Posted
May 6, 2023Actual
Enrollment
149Actual
Phase
Phase 2Phase 3
Conditions
Coronavirus Disease 2019 COVID-19
Interventions
TJ003234
Placebo
Countries
United States
Protocol Section
Identification Module
NCT ID
NCT04341116
Obsolete or Duplicate NCT IDs
Not provided
Organization Study
TJ003234COV201
Secondary IDs
Not provided
Brief Title
Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Official Title
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Safety and Efficacy of TJ003234 in Subjects With Severe Coronavirus Disease 2019 (COVID-19)
Acronym
Not provided
Organization
I-Mab Biopharma US LimitedINDUSTRY
Status Module
Record Verification Date
May 2023
Overall Recruitment Status or Expanded Access Status
Completed
Last Known Status
Not provided
Delayed Posting
Not provided
Why Stopped
Not provided
Expanded Access Info
Not provided
Start Date
Apr 11, 2020Actual
Primary Completion Date
Feb 7, 2022Actual
Completion Date
Feb 7, 2022Actual
First Submitted Date
Apr 4, 2020
First Submission Date that Met QC Criteria
Apr 9, 2020
First Posted Date
Apr 10, 2020Actual
Results Waived
Not provided
Results First Submitted Date
Feb 6, 2023
Results First Submitted that Met QC Criteria
May 3, 2023
Results First Posted Date
May 6, 2023Actual
Certification/Extension (aka Delayed Results) First Submitted Date
Not provided
Certification/Extension First Submitted that Passed QC Review
Not provided
Certification/Extension First Posted Date
Not provided
Last Update Submitted Date
May 3, 2023
Last Update Posted Date
May 6, 2023Actual
Sponsor/Collaborators Module
Responsible Party, by Official Title
Sponsor
Lead Sponsor
I-Mab Biopharma US LimitedINDUSTRY
Collaborators
Not provided
Oversight Module
Has Data Monitoring Committee (DMC)
Yes
Is FDA Regulated Drug
Yes
Is FDA Regulated Device
No
Is Unapproved Device
Not provided
Pediatric Postmarket Surveillance of a Device Product
Not provided
Product Exported from US
Not provided
FDAAA801 Violation
Not provided
Description Module
Brief Summary
This is a randomized, double-blind, placebo-controlled, multi-center trial to evaluate the safety and efficacy of TJ003234 administered as an intravenous (IV) infusion in subjects with severe COVID-19 under supportive care, and to assess the effect of TJ003234 on the levels of cytokines.
Detailed Description
Not provided
Conditions Module
Conditions
Coronavirus Disease 2019 COVID-19
Keywords
Not provided
Design Module
Study Type
Interventional
Number of References to an Expanded Access Study
Not provided
Expanded Access Types
Not provided
Patient Registry
Not provided
Target Follow-Up Duration
Not provided
Phases
Phase 2Phase 3
Interventional Study Design
Allocation
Biospecimen
No data available
No data is available for this block.
Enrollment
149Actual
Arms/Interventions Module
Arm Groups
Label
Type
Description
Intervention Names
TJ003234 Medium Dose
Experimental
Drug: TJ003234
TJ003234 Low Dose
Experimental
Part 1 only
Drug: TJ003234
Placebo
Placebo Comparator
Drug: Placebo
TJ003234 High Dose
Experimental
Part 2 Phase 3 only
Drug: TJ003234
Interventions
Name
Type
Description
Arm Group Labels
Other Names
TJ003234
Drug
patients receive a single infusion
TJ003234 High Dose
TJ003234 Low Dose
TJ003234 Medium Dose
Outcomes Module
Primary Outcomes
Measure
Description
Time Frame
Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline
Free of mechanical ventilation was defined as proportion of subjects who scores 1 to 5 in the following 8-category ordinal scale.
8, death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT) or pressors; 6, intubation and mechanical ventilation; 5, non-invasive mechanical ventilation (NIV) or high-flow oxygen; 4, hospitalization with oxygen by mask or nasal prongs; 3. Hospitalization without oxygen supplementation; 2, limitation of activities, discharge from hospital; and 1, no limitation of activities, discharge from hospital.
Day 1 through Day 30
Secondary Outcomes
Measure
Description
Time Frame
Percentage of Recovery by Day 14
Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.
Day 1 through Day 14
Percentage of Subjects Recovered on Day 30
Other Outcomes
Not provided
Eligibility Module
Eligibility Criteria
Inclusion Criteria:
Age: 18 years or older (including 18 years); male or female
Laboratory-confirmed SARS-CoV-2 or COVID-19 infection as determined by polymerase chain reaction (PCR) or other commercial or public health assay.
Bilateral lung infection confirmed by imaging.
Severe disease that meets one of the following conditions: (i) At rest, finger blood oxygen saturation ≤ 93% or PaO2/FiO2 ≤ 300 mmHg; (ii) Requiring non-invasive or invasive mechanical ventilation; OR (iii) Requiring high flow oxygen ≥ 15L/min
Hospitalized for no more than 5 calendar days at the time of screening
Exclusion Criteria:
Any previous and/or current clinically significant disease or condition that has not been stable within 3 months prior to enrollment, or acute illness, planned medical/ surgical procedure, or any trauma that occurred within 2 weeks prior to enrollment.
Pulmonary interstitial disease, pulmonary alveolar proteinosis, and pulmonary granulomatosis.
Cardiovascular event in the 3 months prior to study drug administration: acute myocardial infarction or unstable angina pectoris, severe arrhythmia (multiple sources of frequent ventricular premature beat, ventricular tachycardia and ventricular fibrillation); New York Heart Association Classification (NYHA): Class III-Class IV.
Blood system disorders or routine blood analysis test abnormalities: Hemoglobin < 8 g/dL; Absolute neutrophil count (ANC) <1500 × 109/L; Platelets < 50 × 109/L.
Dependence on glucocorticoid treatment equivalent to methylprednisolone 2 mg/kg/ day or more or long-term use of anti-rejection or immunomodulatory drugs.
Subjects that have been on invasive mechanical ventilation for ≥120 hours at the time of dosing
Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.
Day 1 through Day 30
All-cause Mortality Rate by Day 30
The percentage of subjects who deceased by any cause.
Day 1 through Day 30
Time to Recovery Among Subjects Alive by Day 30
Time to sustained recovery
Day 1 through Day 30
Length of Hospitalization
Duration of hospitalization
Day 1 through Day 30
Sylmar
California
91342
United States
Georgetown University Hospital
Washington D.C.
District of Columbia
20007
United States
The GW Medical Faculty Associates
Washington D.C.
District of Columbia
20037
United States
University of Miami
Miami
Florida
33146
United States
OSF Healthcare Saint Francis Medical Center
Peoria
Illinois
61637
United States
Indiana University Health
Indianapolis
Indiana
46202
United States
Medpharmics, LLC
Metairie
Louisiana
70006
United States
Ochsner Medical Center
New Orleans
Louisiana
70121
United States
Brigham and Women's Hospital
Boston
Massachusetts
02115
United States
University of Mississippi Medical Center
Jackson
Mississippi
39216
United States
University Medical Center of Southern Nevada
Las Vegas
Nevada
89102
United States
UNM Hospitals
Albuquerque
New Mexico
87106
United States
Houston Methodist Hospital
Houston
Texas
77030
United States
FG002
Placebo (Part 1)
Subjects treated with placebo in Part 1
FG003
TJ003234 6mg/kg (Part 2)
Subjects treated with 6mg/kg in Part 2
FG004
TJ003234 10mg/kg (Part 2)
Subjects treated with 10mg/kg of TJ003234
FG005
Placebo (Part 2)
Subjects treated with placebo in Part 2
FG0008 subjects
FG0018 subjects
FG0028 subjects
FG00377 subjectsITT population
FG0046 subjects
FG00542 subjectsITT population
COMPLETED
FG0007 subjects
FG0016 subjects
FG0026 subjects
FG00366 subjects
FG0045 subjects
FG00534 subjects
NOT COMPLETED
FG0001 subjects
FG0012 subjects
FG0022 subjects
FG00311 subjects
FG0041 subjects
FG0058 subjects
Type of Units Analyzed
Not provided
Arm/Group Information
ID
Title
Description
BG000
TJ003234 3mg/kg (Part 1)
subjects treated by 3mg/kg of TJ003234
BG001
TJ003234 6mg/kg (Part 1)
subjects treated by 6mg/kg of TJ003234 in Part 1
BG002
Placebo (Part 1)
subjects treated by placebo in Part 1
BG003
TJ003234 6mg/kg (Part 2)
subjects treated by 6mg/kg of TJ003234 in Part 2
BG004
TJ003234 10mg/kg (Part 2)
subjects treated by 10 mg/kg of TJ003234 in Part 2
BG005
Placebo (Part 2)
subjects treated by placebo in Part 2
BG006
Total
Total of all reporting groups
Denominators
Units
Counts
Participants
BG0008
BG0018
BG0028
BG00377
BG0046
BG00542
BG006149
Baseline Measures
Title
Description
Population Description
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Denominator Units Selected
Denominators
Classes
Age, Continuous
Mean
Full Range
years
Title
Denominators
Categories
Title
Measurements
BG00051.9(36 to 80)
BG00158.4(39 to 75)
BG00258(19 to 80)
BG003
Sex: Female, Male
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Female
BG0004
BG0013
BG002
Ethnicity (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Hispanic or Latino
BG0000
BG0011
BG002
Race (NIH/OMB)
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
American Indian or Alaska Native
BG0000
BG0010
BG002
Region of Enrollment
Number
participants
Title
Denominators
Categories
United States
Title
Measurements
BG0008
BG0018
BG002
Height
Mean
Full Range
cm
Title
Denominators
Categories
Title
Measurements
BG000168.8(144.8 to 190.5)
BG001166.8(147.3 to 185.4)
BG002
Weight
Mean
Full Range
kg
Title
Denominators
Categories
Title
Measurements
BG000101.4(43.9 to 161.0)
BG00188.0(74.0 to 138.3)
BG002
Mechanical Ventilation
Count of Participants
Participants
Title
Denominators
Categories
Title
Measurements
Yes
BG0003
BG0013
BG002
Type
Title
Description
Population Description
Reporting Status
Anticipated Posting Date
Parameter Type
Dispersion Type
Unit of Measure
Calculate Percentage
Time Frame
Units Analyzed
Denominator Units Selected
Arm/Group Information
Denominators
Classes
Analyses
Primary
Percentage of Subjects Alive and Free of Mechanical Ventilation Among Subjects Who Are Free of Mechanical Ventilation at Baseline
Free of mechanical ventilation was defined as proportion of subjects who scores 1 to 5 in the following 8-category ordinal scale.
8, death; 7, ventilation in addition to extracorporeal membrane oxygen (ECMO), continuous renal replacement therapy (CRRT) or pressors; 6, intubation and mechanical ventilation; 5, non-invasive mechanical ventilation (NIV) or high-flow oxygen; 4, hospitalization with oxygen by mask or nasal prongs; 3. Hospitalization without oxygen supplementation; 2, limitation of activities, discharge from hospital; and 1, no limitation of activities, discharge from hospital.
All subjects randomized to treatment who were mechanical ventilation free at baseline was collected only for Part 2 arms/groups. Data was not collected from the Part 1 Arms/Groups.
Posted
Count of Participants
Participants
Day 1 through Day 30
ID
Title
Description
OG000
TJ003234 6mg/kg (Part 1)
subjects treated with TJ003234 6mg/kg -Part 1
OG001
Placebo (Part 1)
subjects treated with placebo (Part 1)
OG002
TJ003234 6mg/kg (Part 2)
subjects treated with TJ003234 6mg/kg (mITT population)
OG003
TJ0032034 10mg/kg (Part 2)
subjects treated with TJ003234 10mg/kg (mITT population)
OG004
Placebo (Part 2)
Subjects treated with placebo (mITT population)
Units
Counts
Participants
OG0000
OG0010
OG00267
OG003
Title
Denominators
Categories
Title
Measurements
OG00256
OG0035
OG00427
Group IDs
Group Description
Statistical Method
Statistical Comment
P-Value
P-Value Comment
Parameter Type
Parameter Value
Dispersion Type
Dispersion Value
Confidence Interval Sides
Confidence Interval %
CI Lower Limit
CI Upper Limit
CI Lower Limit Comment
CI Upper Limit Comment
Estimate Comment
Tested Non-Inferiority
Non-Inferiority Type
Non-Inferiority Comment
Other Analysis Description
OG002
OG003
Fisher Exact
.28
Median Difference (Final Values)
9
Standard Error of the Mean
8.5
2-Sided
95
-6.5
27
Superiority
Secondary
Percentage of Recovery by Day 14
Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.
All subjects randomized was collected only for Part 2 arms/groups. Data was not collected from the Part 1 Arms/Groups.
Posted
Count of Participants
Participants
Day 1 through Day 14
ID
Title
Description
OG000
TJ003234 6mg/kg (Part 1)
subjects treated with TJ003234 6mg/kg part 1
OG001
Placebo (Part 1)
subjects treated with placebo (part 1)
OG002
TJ003234 6mg/kg (Part 2)
subjects treated with 6mg/kg TJ003234-(ITT population)
OG003
TJ003234 10mg/kg (Part 2)
subjects treated10mg/kg TJ003234 (ITT population)
OG004
Placebo (Part 2)
Secondary
Percentage of Subjects Recovered on Day 30
Sustained recovery in clinical status was defined as patients who have hospitalization without oxygen supplement or discharge from hospital.
All subjects randomized was collected only for Part 2 arms/groups. Data was not collected from the Part 1 Arms/Groups.
Posted
Count of Participants
Participants
Day 1 through Day 30
ID
Title
Description
OG000
TJ003234 6mg/kg (Part 1)
subjects treated with 6mg/kg part 1
OG001
Placebo (Part 1)
subjects treated with placebo part 1
OG002
TJ003234 6mg/kg (Part 2)
subjects treated with 6mg/kg TJ003234 (ITT population)
OG003
TJ003234 10mg/kg (Part 2)
subjects treated with 10mg/kg placebo- ITT population
OG004
Placebo (Part 2)
Secondary
All-cause Mortality Rate by Day 30
The percentage of subjects who deceased by any cause.
All subjects randomized was collected only for Part 2 arms/groups. Data was not collected from the Part 1 Arms/Groups.
Posted
Count of Participants
Participants
Day 1 through Day 30
ID
Title
Description
OG000
TJ003234 6mg/kg (Part 1)
subjects treated with TJ003234 6mg/kg - part 1
OG001
Placebo (Part 1)
subjects treated with placebo
OG002
TJ003234 6mg/kg (Part 2)
subjects treated with 6 mg/kg TJ003234 (ITT population)
OG003
TJ003204 10mg/kg (Part 2)
subjects who were treated with 10mg/kg TJ003234 (ITT population)
OG004
Placebo (Part 2)
subjects treated by placebo (ITT population)
Secondary
Time to Recovery Among Subjects Alive by Day 30
Time to sustained recovery
All subjects randomized without mechanical ventilation Part 2. Part 1 is designed as a randomized, double-blind, placebo-controlled, 3-arm, parallel-group study to evaluate the safety of plonmarlimab in subjects with severe COVID-19. So, no available efficacy data for this part.
Posted
Median
95% Confidence Interval
days
Day 1 through Day 30
ID
Title
Description
OG000
TJ003234 6mg/kg (Part 1)
subjects treated with TJ003234 6mg/kg- part 1
OG001
Placebo (Part 1)
subjects treated with placebo
OG002
TJ003234 6mg/kg (Part 2)
subjects treated with 6mg/kg TJ003234 (mITT population)
OG003
TJ004309 10mg/kg (Part 2)
subjects treated with 10mg/kg TJ0032034 (mITT population)
OG004
Placebo (Part 2)
Secondary
Length of Hospitalization
Duration of hospitalization
All subjects without mechanical ventilation- Part 2. Part 1 is designed as a randomized, double-blind, placebo-controlled, 3-arm, parallel-group study to evaluate the safety of plonmarlimab in subjects with severe COVID-19. So, no available efficacy data for this part.
Posted
Median
95% Confidence Interval
days
Day 1 through Day 30
ID
Title
Description
OG000
TJ003234 6mg/kg (Part 1)
subjects treated with 6mg/kg
OG001
Placebo (Part 1)
subjects treated with placebo
OG002
TJ003234 6mg/kg (Part 2)
subjects treated with 6 mg/kg TJ003234 (mITT population)
OG003
TJ003234 10mg/kg (Part 2)
subjects treated with 10mg/kg of TJ003234 (mITT population)
OG004
Placebo (Part 2)
Time Frame
All adverse events will be collected from the day of informed consent to Day 30.
Description
Disease progression or deterioration is also recorded as an AE/SAE, regardless of whether the Investigator assesses that it is related to the study drug. Signs and symptoms from the following may be considered AEs: drug overdose, withdrawal or misuse, drug interactions, extravasations, exposure during pregnancy/breastfeeding. Safety reporting results are based on ITT population.
All-Cause Mortality Comment
Not provided
Arm/Groups
ID
Title
Description
Deaths (Affected)
Deaths (At Risk)
Serious Events (Affected)
Serious Events (At Risk)
Other Events (Affected)
Other Events (At Risk)
EG000
TJ003234 3 mg/kg (Part 1)
subjects treated with 3mg/kg TJ003234 (Part 1) (Safety population)
1
8
2
8
0
8
EG001
TJ003234 6mg/kg (Part 1)
subjects treated with 6 mg/kg TJ003234 (Safety population)
1
8
4
8
0
8
EG002
Placebo (Part 1)
subjects treated by placebo (Safety population)
2
8
2
8
0
8
EG003
TJ003234 6 mg/kg (Part 2)
subjects treated with 6mg/kg TJ003234 (Safety population)
11
77
22
77
0
77
EG004
TJ003234 10mg/kg (Part 2)
subjects treated with 10mg/kg (Safety population)
1
6
1
6
0
6
EG005
Placebo (Part 2)
subjects treated by placebo (Safety population)
10
42
16
42
0
42
Serious Adverse Events
Term
Organ System
Source Vocabulary
Assessment Type
Notes
Statistical Information
ADRENAL INSUFFICIENCY
Endocrine disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG0031 events1 affected77 at risk
EG0040 events0 affected6 at risk
EG0050 events0 affected42 at risk
Cardiac Arrest
Cardiac disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0011 events1 affected8 at risk
EG0020 events0 affected8 at risk
EG003
MYOCARDIAL ISCHEMIA
Cardiac disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
WORSENING BRADYCARDIA
Cardiac disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
TAKOTSUBO CARDIOMYOPATHY
Cardiac disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
MULTI ORGAN SYSTEM FAILURE
General disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
SEPTIC SHOCK
Infections and infestations
Systematic Assessment
EG0000 events0 affected8 at risk
EG0011 events1 affected8 at risk
EG0020 events0 affected8 at risk
EG003
BACTEREMIA
Infections and infestations
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
(Worsening) PNEUMONIA (due to COVID-19)
Infections and infestations
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
SEPSIS
Infections and infestations
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
SELF-EXTUBATION WITH COMPLICATION
Injury, poisoning and procedural complications
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
INTRACRANIAL HEMORRHAGIC TRANSFORMATION
Nervous system disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
SUBARACHNOID HEMORRHAGE
Nervous system disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
ACUTE KIDNEY INJURY
Renal and urinary disorders
Systematic Assessment
EG0001 events1 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
(WORSENING) HYPOXIC RESPIRATORY FAILURE
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
(WORSENING) RESPIRATORY FAILURE DUE TO COVID-19
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
PNEUMOTHORAX
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
PULMONARY EMBOLISM
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
PULMONARY FIBROSIS
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
WORSENING BILATERAL PNEUMONITITS
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
Acute respiratory distress syndrome
Respiratory, thoracic and mediastinal disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
SUBCUTANEOUS EMPHYSEMA
Skin and subcutaneous tissue disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
DISTRIBUTIVE SHOCK
Vascular disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
NECROTIC DIGITS
Vascular disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
HEMORRHAGIC SHOCK
Vascular disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
CARDIOGENIC SHOCK
Cardiac disorders
Systematic Assessment
EG0000 events0 affected8 at risk
EG0010 events0 affected8 at risk
EG0020 events0 affected8 at risk
EG003
ATRIAL FIBRILLATION WITH RAPID VENTRICULAR RESPONSE